

Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis

Kentaro Hayakawa¹, Makoto Kurano², Junichi Ohya¹, Takeshi Oichi¹, Kuniyuki Kano³, Masako Nishikawa², Baasanjav Uranbileg², Ken Kuwajima⁴, Masahiko Sumitani^{4,5}, Sakae Tanaka¹, Junken Aoki³, Yutaka Yatomi², Hirotaka Chikuda⁶

¹Department of Orthopaedic Surgery, The University of Tokyo, Faculty of Medicine, Tokyo, Japan

²Department of Clinical Laboratory Medicine, The University of Tokyo Hospital, Tokyo, Japan


³Graduate School of Pharmaceutical Sciences, Tohoku University, Molecular and Cellular Biochemistry, Sendai, Japan

⁴Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, Tokyo, Japan

⁵Department of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan

⁶Department of Orthopaedic Surgery, Gunma University, Graduate School of Medicine, Maebashi, Japan

Supplementary Figure S1



Supplementary Figure S1: Distribution of NPSI and ZCQ scores. Patients were categorized into two groups as Mild/Severe.

NPSI, Neuropathic Pain Symptom Inventory; ZCQ, Zurich Claudication Questionnaire